Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2019

01-06-2019 | Brief Research Article

Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies

Author: O. Abdel-Rahman

Published in: Clinical and Translational Oncology | Issue 6/2019

Login to get access

Abstract

Background

The current analysis aims to evaluate the impact of statin co-treatment on the survival of patients with metastatic pancreatic cancer.

Methods

This is a pooled analysis of de-identified patient data from two clinical trials (NCT01124786; NCT00844649). Overall and progression-free survival according to patient subsets (patients who received or who did not receive statins) were assessed through Kaplan–Meier analysis and log-rank test. Univariate and multivariate Cox regression analysis was performed to evaluate different factors potentially affecting overall and progression-free survival. Propensity score matching was performed to address heterogeneity in baseline characteristics of different subgroups of patients.

Results

A total of 797 patients were assessed in the current study; of which 156 patients received statins and 641 did not receive statins. Using Kaplan–Meier survival estimates, patients who received statins seem to have better overall and progression-free survival compared to patients who did not (P = 0.008; P < 0.001, respectively). In multivariate analysis for factors affecting overall survival, the following factors were associated with worse overall survival: worse performance status (P < 0.001), no statin use (P = 0.044) and multiple sites of metastatic disease (P = 0.023); likewise in multivariate analysis for factors affecting progression-free survival, the following factors were associated with worse progression-free survival: worse performance status (P < 0.001), gemcitabine elaidate chemotherapy (P = 0.015) and no statin use (P = 0.048). Following propensity score matching and using Kaplan–Meier estimates, statin use was also associated with better overall and progression-free survival (P = 0.005; P = 0.040, respectively).

Conclusion

Statin use seems to be associated with better overall survival among patients with metastatic pancreatic cancer treated with first-line chemotherapy. Prospective studies designed specifically to assess this potential effect of statins are needed.
Literature
1.
2.
Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688.CrossRefPubMedPubMedCentral
3.
Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083–93.CrossRefPubMed
4.
Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, et al. Comorbidity,age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA. 3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012;48(10):1434–42.CrossRefPubMed
5.
6.
Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11(3):306–15.CrossRefPubMed
7.
Chae YK, Yousaf M, Malecek MK, Carneiro B, Chandra S, Kaplan J, et al. Statins as anti-cancer therapy; can we translate preclinical and epidemiologic data into clinical benefit? Discov Med. 2015;20(112):413–27.PubMed
8.
Lee HS, Lee SH, Lee HJ, Chung MJ, Park JY, Park SW, et al. Statin use and its impact on survival in pancreatic cancer patients. Medicine. 2016;95(19):e3607.CrossRefPubMedPubMedCentral
9.
Jeon CY, Pandol SJ, Wu B, Cook-Wiens G, Gottlieb RA, Merz CN, et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One. 2015;10(4):e0121783.CrossRefPubMedPubMedCentral
10.
11.
Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hent1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013;31(35):4453–61.CrossRefPubMed
12.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRef
13.
14.
Wu BU, Chang J, Jeon CY, Pandol SJ, Huang B, Ngor EW, et al. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol. 2015;110(8):1233–9.CrossRefPubMedPubMedCentral
15.
Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, et al. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin Gastroenterol Hepatol. 2018;16(8):1300.e3–1306.e3.CrossRef
16.
Huang BZ, Chang JI, Li E, Xiang AH, Wu BU. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J Natl Cancer Inst. 2016;109(5).
17.
18.
Dong Y-W, Shi Y-Q, He L-W, Cui X-Y, Su P-Z. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget. 2017;8(33):55478–88.PubMedPubMedCentral
Metadata
Title
Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies
Author
O. Abdel-Rahman
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1992-3

Other articles of this Issue 6/2019

Clinical and Translational Oncology 6/2019 Go to the issue

Research Article

Laparoscopy adjuvant total colorectal resection for the treatment of familial adenomatous polyposis (FAP)

Review Article

Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives

Research Article

Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes

Research Article

Oncologic outcomes of nephron-sparing surgery in patients with T1 multifocal renal cell carcinoma

Brief Research Article

Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

Correction

Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits